EXEL — Exelixis, Inc.

Exelixis Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenues: Approximately $598 million, up from $653 million in Q3 2024.
• Cabozantinib Franchise: Generated net product revenues of approximately $543 million, a 14% year-over-year increase.
• Gross to Net Ratio: 30.4% for the cabozantinib franchise, with expectations to maintain around 30% for the year.
• Operating Expenses: Approximately $361 million, a slight increase from $355 million in Q2 2025, primarily due to a $19.8 million restructuring charge.
• GAAP Net Income: Approximately $193.6 million ($0.72 per share basic).
• Non-GAAP Net Income: Approximately $217.9 million ($0.81 per share basic).
• Cash and Marketable Securities: Approximately $1.6 billion.
• Share Repurchases: Approximately $99 million in Q3, with an additional $750 million authorized for repurchase.

2. Strategic Updates and Business Highlights:

• Cabozantinib Performance: Continued strong growth, especially in the neuroendocrine tumor (NET) segment, which saw a 50% increase in demand quarter-over-quarter. The company expects to exceed $100 million in revenue from this indication in 2025.
• Zanzalintinib Development: Rapid advancement with seven ongoing pivotal trials. Positive results from the STELLAR-303 trial in colorectal cancer (CRC) are expected to lead to an NDA filing by December 2025.
• Pipeline Progress: The early-stage pipeline includes four molecules in clinical development, with ongoing efforts to explore new indications and combinations for zanzalintinib.

3. Forward Guidance and Outlook:

• Revenue Guidance: Total revenues projected between $2.3 billion and $2.35 billion for 2025, with net product revenues between $2.1 billion and $2.15 billion.
• Cost of Goods Guidance: Approximately 4% of net product revenues.
• R&D Expense Guidance: Lowered to $850 million to $900 million.
• SG&A Expense Guidance: Tightened to $500 million to $525 million.
• Effective Tax Rate Guidance: Lowered to between 17% and 18%.

4. Bad News, Challenges, or Points of Concern:

• Operating Expenses Increase: The rise in operating expenses due to restructuring charges could indicate potential challenges in cost management.
• Market Competition: Concerns about competitive pressures from emerging therapies, particularly in the CRC space, where Merck's recent positive trial results could impact zanzalintinib's market entry.
• Regulatory Risks: The ongoing government shutdown may delay the NDA submission for zanzalintinib, impacting the timeline for market entry.

5. Notable Q&A Insights:

• Market Feedback on Zanzalintinib: Positive physician feedback post-ESMO regarding zanzalintinib's overall survival benefits, with expectations to capture market share from competitors in the fragmented CRC market.
• Clinical Trial Design: Discussion on the rationale for using sunitinib as a comparator in the STELLAR-304 trial, emphasizing its relevance as a standard of care.
• Concerns Over Cannibalization: Questions regarding potential market overlap between cabozantinib and zanzalintinib in the NET space, with management expressing confidence in the distinct positioning of both therapies.
• Emerging Bispecific Therapies: Acknowledgment of the competitive landscape with new bispecific agents entering the CRC market, but management remains optimistic about zanzalintinib's differentiation based on clinical data.

Overall, Exelixis reported strong financial results driven by cabozantinib's performance while positioning zanzalintinib for future growth amid competitive pressures and regulatory uncertainties.